Today: 24 June 2026
Browse Category

NASDAQ:QNCX 10 February 2026 - 18 May 2026

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics was last quoted at $1.15 before Monday’s Nasdaq open after Nantahala Capital Management disclosed 7.52% beneficial ownership. The company’s latest filing reported no current product candidates and raised substantial doubt about its ability to continue as a going concern. Quince is seeking shareholder approval for another reverse stock split at its June 11 meeting. The company remains out of compliance with Nasdaq’s $50 million market value rule.
18 May 2026
·
Upcoming Stock Splits This Week: Nasdaq Reverse Splits Pile Up as Booking, Powell and Pashupati Stand Apart

Upcoming Stock Splits This Week: Nasdaq Reverse Splits Pile Up as Booking, Powell and Pashupati Stand Apart

NextPlat, MultiSensor AI, Cenntro, and Quince Therapeutics will begin trading Monday on a reverse-split basis, with ratios ranging from 1-for-10 to 1-for-60. Several other Nasdaq-listed firms, including Huachen AI Parking and Akanda, are also set for reverse splits. Last week saw forward splits from Booking Holdings and Powell Industries. Cenntro and Quince both disclosed ongoing Nasdaq compliance concerns.
13 April 2026
·······
Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive

Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive

Quince Therapeutics shares jumped about 48% to 78 cents in premarket trading Wednesday after the company hired LifeSci Capital to explore strategic alternatives and liability restructuring. The move follows a failed late-stage drug trial and the resignation of five board directors. The stock surged from 13 cents Monday to 52.8 cents Tuesday on heavy volume. Investors await further disclosures or a timeline for next steps.
11 February 2026
·
Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move

Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move

Quince Therapeutics shares dropped 6.6% to $0.13 in premarket trading after the company hired LifeSci Capital to advise on strategic alternatives and liability restructuring. The move follows a failed Phase 3 trial in late January and the resignation of five directors. Quince said it will not provide further updates unless its board approves a specific action.
10 February 2026
·

Stock Market Today

  • Lean Hog Futures Show Mixed Trading with Deferred Contracts Rising
    June 24, 2026, 3:22 PM EDT. Lean hog futures exhibited mixed trading Wednesday, with nearby contracts falling 15 to 20 cents while deferred contracts gained up to 70 cents. The USDA's national base hog price was not reported due to thin trade, and the CME Lean Hog Index declined 17 cents to $91.47. The USDA pork carcass cutout value fell 41 cents to $94.84 per hundredweight. Hog slaughter numbers stood at 486,000 head Tuesday, totaling 942,000 for the week, down 21,000 from the previous week but up nearly 13,000 year-over-year. July and August hog futures declined, while October contracts advanced slightly, reflecting varied market sentiment amid supply fluctuations.
MARA Holdings tumbles with miners on bitcoin slide, investors eye share-plan vote

MARA Holdings tumbles with miners on bitcoin slide, investors eye share-plan vote

24 June 2026
MARA shares plunged nearly 8% to $13.54 after shareholders approved an 18 million-share increase to its equity incentive plan, raising dilution risk as bitcoin slumped 4.9% and company insiders disclosed recent stock sales; Citizens began coverage with a market outperform rating and $24 price target, but first-quarter revenue fell 18% and net loss widened to $1.3 billion, driven by a $1 billion loss on digital assets.
Go toTop